GlassScriptPhysician profile
Carrie A Elam
NPI 1326473984
$10,059.90
in general payments reported to CMS, 2019-2025
33 companies · $2,142 in 2025
The $2,142 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,603 · 2022: $1,746 · 2023: $1,758 · 2024: $2,811 · 2025: $2,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,707 · Consulting Fee: $644 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,706.77 |
| Consulting Fee | $644.00 |
| Education | $359.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,571.27 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,326.63 | 2022-2025 | Sotyktu |
| Abbvie INC. | $1,155.37 | 2021-2025 | |
| Genzyme Corporation | $1,154.61 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $800.51 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $785.91 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $674.55 | 2021-2025 | Dupixent |
| Ucb, INC. | $344.35 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $278.74 | 2021-2025 | |
| Amgen INC. | $273.03 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $265.19 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Incyte Corporation | $211.16 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $208.40 | 2021-2024 | Olumiant, Taltz, Ebglyss |
| Leo Pharma INC. | $146.86 | 2021-2024 | Adbry |
| Helsinn Therapeutics (U.S.), INC. | $102.93 | 2021-2023 | Valchlor |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $80.22 | 2022-2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Verrica Pharmaceuticals INC. | $79.34 | 2023-2024 | Ycanth |
| Epi Health, LLC | $66.38 | 2021-2022 | |
| Botanix Sb INC | $59.59 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $58.24 | 2023-2024 | |
| Almirall LLC | $57.18 | 2022-2024 | Seysara |
| Kyowa Kirin, INC. | $56.84 | 2022-2024 | Poteligeo |
| Mayne Pharma Commercial LLC | $48.06 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $35.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.42 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.15 | 2024 | Jublia |
| Astrazeneca Pharmaceuticals LP | $20.09 | 2023 | |
| Seqirus USA INC | $19.38 | 2021 | |
| Cipher Pharmaceuticals US LLC | $15.59 | 2025 | Natroba, Spinosad |
| Arcutis Biotherapeutics, INC. | $14.17 | 2025 | Zoryve |
| Smith+Nephew, INC. | $12.79 | 2021 | |
| Genentech USA, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Elam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.